Get the Stockscreener App
2.20
0.45%
-0.010
After Hours:
2.17
-0.03
-1.36%
Tscan Therapeutics Inc stock is traded at $2.20, with a volume of 505.59K.
It is down -0.45% in the last 24 hours and up +25.00% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$2.21
Open:
$2.22
24h Volume:
505.59K
Relative Volume:
1.41
Market Cap:
$115.44M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.2291
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+7.32%
1M Performance:
+25.00%
6M Performance:
+77.42%
1Y Performance:
-59.18%
1-Day Range:
$2.13
$2.29
1-Week Range:
$1.90
$2.33
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
2.20 | 125.41M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Quantitative breakdown of TScan Therapeutics Inc. recent moveJuly 2025 Decliners & Capital Efficient Trade Techniques - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsMarket Weekly Review & Community Supported Trade Ideas - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fearsQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
What MACD and RSI say about TScan Therapeutics Inc.July 2025 Technicals & Verified Entry Point Signals - newser.com
TScan Therapeutics Inc. stock daily chart insightsJuly 2025 PreEarnings & Verified Technical Trade Signals - newser.com
How to forecast TScan Therapeutics Inc. trends using time series2025 Big Picture & Safe Entry Zone Identification - newser.com
Short interest data insights for TScan Therapeutics Inc.July 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
Will TScan Therapeutics Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Based Buy/Sell Signal Reports - newser.com
Will TScan Therapeutics Inc. stock continue dividend increasesWeekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
What the charts say about TScan Therapeutics Inc. today2025 Winners & Losers & AI Driven Stock Reports - newser.com
Is TScan Therapeutics Inc a good long term investmentSwing Trading Ideas & Fast Growing Capital Growth - earlytimes.in
Goldman Sachs Group Inc. Buys 9,676 Shares of TScan Therapeutics, Inc. $TCRX - Defense World
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):